A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2018
At a glance
- Drugs AMG 337 (Primary)
- Indications Clear cell sarcoma
- Focus Therapeutic Use
- Sponsors NantPharma
- 06 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 06 Jun 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
- 03 Jan 2018 Status changed from not yet recruiting to recruiting.